DE60327075D1 - Der entzündungsreaktionen - Google Patents

Der entzündungsreaktionen

Info

Publication number
DE60327075D1
DE60327075D1 DE60327075T DE60327075T DE60327075D1 DE 60327075 D1 DE60327075 D1 DE 60327075D1 DE 60327075 T DE60327075 T DE 60327075T DE 60327075 T DE60327075 T DE 60327075T DE 60327075 D1 DE60327075 D1 DE 60327075D1
Authority
DE
Germany
Prior art keywords
inflammatory reactions
inflammation
present
reactions
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327075T
Other languages
English (en)
Inventor
Philippe A Tessier
Carle Ryckman
Karen Vandal
Pascal Rouleau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Laval
Original Assignee
Universite Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Laval filed Critical Universite Laval
Application granted granted Critical
Publication of DE60327075D1 publication Critical patent/DE60327075D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60327075T 2002-07-05 2003-06-20 Der entzündungsreaktionen Expired - Lifetime DE60327075D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39352002P 2002-07-05 2002-07-05
PCT/CA2003/000939 WO2004004770A1 (en) 2002-07-05 2003-06-20 Chemotactic factor inhibitor for modulating inflammatory reactions

Publications (1)

Publication Number Publication Date
DE60327075D1 true DE60327075D1 (de) 2009-05-20

Family

ID=30115596

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60327075T Expired - Lifetime DE60327075D1 (de) 2002-07-05 2003-06-20 Der entzündungsreaktionen

Country Status (7)

Country Link
US (4) US7553488B2 (de)
EP (1) EP1519749B1 (de)
AT (1) ATE427758T1 (de)
AU (1) AU2003236762A1 (de)
CA (1) CA2489860C (de)
DE (1) DE60327075D1 (de)
WO (1) WO2004004770A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084928A1 (en) * 2003-03-28 2004-10-07 UNIVERSITé LAVAL S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
EP1784216A4 (de) * 2004-07-13 2009-06-03 Univ Laval S100 proteinhemmer zur behandlung von leukämie
WO2006122723A1 (en) * 2005-05-19 2006-11-23 Vaecgene Biotech Gmbh Method for the prevention and/or treatment of autoimmune disease or allogeneic transplant rejections
AU2009240885A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Pharmaceutical agent for promoting the functional regeneration of damaged tissue
KR20160070169A (ko) 2008-04-30 2016-06-17 가부시키가이샤 제노믹스 생체내 기능적 세포의 고효율 채취법
US8283131B2 (en) * 2008-10-28 2012-10-09 Assistance Publique-Hopitaux De Paris Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock
CA2778759A1 (en) 2009-10-28 2011-05-05 Genomix Co., Ltd. Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood
AU2011322482B2 (en) 2010-10-30 2017-03-23 Oxford University Innovation Limited Treatment for Dupuytren's disease
CA2834255C (en) 2011-04-26 2021-11-02 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
WO2012155049A1 (en) * 2011-05-11 2012-11-15 Medimmune, Llc Treatment of lung inflammation
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
TR201807769T4 (tr) 2012-10-25 2018-06-21 Genomix Co Ltd HMGB1 fragmanı kullanılarak spinal kord yaralanmasının tedavi edilmesine yönelik yeni yöntem.
US10005833B2 (en) * 2015-01-02 2018-06-26 Washington State University Methods of treating inflammation associated airway diseases and viral infections
JP6953033B2 (ja) * 2015-07-13 2021-10-27 ユニヴェルシテ ラヴァル ヒト化抗ｓ１００ａ９抗体およびその使用
CA2998410A1 (en) 2015-09-14 2017-03-23 Universite Laval Anti-s100a8 for treating leukemia
EP3439701A4 (de) 2016-04-08 2019-12-11 180 Therapeutics LP Verfahren zur behandlung der dupuytren-krankheit im frühstadium
TWI805565B (zh) 2017-01-27 2023-06-21 日商斯德武利姆股份有限公司 心肌病、陳舊性心肌梗塞及慢性心臟衰竭的治療藥物
KR102457657B1 (ko) * 2017-02-07 2022-10-21 리프스톤 비.브이. 무균성 해리로 인한 임플란트 관련 임플란트 교정 위험을 진단하기 위한 바이오마커
EP3718561A4 (de) 2017-12-01 2021-07-21 Stemrim Inc. Therapeutikum für entzündliche darmerkrankung
WO2020051460A1 (en) * 2018-09-07 2020-03-12 Sanford Burnham Prebys Medical Discovery Institute Methods of diagnosis and treatment of inflammatory bowel disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263072B1 (de) 1986-10-03 1994-03-23 Ciba-Geigy Ag Lymphokin-ähnliche Peptide
ATE228164T1 (de) * 1990-09-05 2002-12-15 Heart Res Inst Ltd Chemotaktische faktoren
US5248825A (en) * 1990-09-20 1993-09-28 Merrell Dow Pharmaceuticals Inc. Calcium uptake inhibitors
EP0961780B1 (de) * 1997-02-12 2007-04-11 Electrophoretics Limited Proteinmarker für lungenkrebs und deren verwendung
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
US6706683B1 (en) * 1998-09-29 2004-03-16 Asahi Kasei Pharma Corporation Method for controlling the release of granules
AU2002364607A1 (en) * 2001-12-28 2003-07-24 The Burnham Institute Novel ligand involved in the transmigration of leukocytes .
WO2004084928A1 (en) * 2003-03-28 2004-10-07 UNIVERSITé LAVAL S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
EP1784216A4 (de) * 2004-07-13 2009-06-03 Univ Laval S100 proteinhemmer zur behandlung von leukämie

Also Published As

Publication number Publication date
CA2489860C (en) 2015-02-10
US8282925B2 (en) 2012-10-09
EP1519749B1 (de) 2009-04-08
US20050288211A1 (en) 2005-12-29
US20090275516A1 (en) 2009-11-05
ATE427758T1 (de) 2009-04-15
US20130273075A1 (en) 2013-10-17
EP1519749A1 (de) 2005-04-06
US7553488B2 (en) 2009-06-30
AU2003236762A1 (en) 2004-01-23
US20140348849A1 (en) 2014-11-27
WO2004004770A1 (en) 2004-01-15
CA2489860A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
DE60327075D1 (de) Der entzündungsreaktionen
DK1590340T3 (da) Histondeacetylase-inhibitorer
MX2021000780A (es) Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1.
DE60143520D1 (de) Inhibitoren der histon-deacetylase
WO2012178208A3 (en) Selective inhibitors of histone deacetylase isoform 6 and methods thereof
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
EA200802285A1 (ru) Бивалентные миметики smac и их применения
BRPI1013388A2 (pt) composição de limpeza que compreende uma alfa-amilase e uma protease e método de limpeza de um tecido ou superficie dura
DK1660507T3 (da) Proteasominibitorer og metoder til anvendelse heraf
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
DK1846424T3 (da) Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
EA201500769A1 (ru) Ингибиторы е1 активирующих ферментов
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
EA200900285A1 (ru) Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
EP3354640A3 (de) Mif-hemmer und verwendungen davon
EA201890903A1 (ru) Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
EA201790882A1 (ru) Способы и композиции для терапии рака печени
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
MX2009006542A (es) Inhibidores de histona desacetilasa y sus profarmacos.
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
GB2441727A (en) Corrosion inhibitor for acids
TW200635587A (en) Inducible nitric oxide synthase dimerization inhibitors
DE602007008723D1 (de) Selektive rock-proteinkinasehemmer und ihre verwendung
WO2006023866A3 (en) Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
TW200621744A (en) Mercaptoamides as histone deacetylase inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition